Pharmaceutical Key Trends 2010

Introduction

Pharma faces a number of key resistors to growth including the impending 2011 patent cliff which is set to erode $78 billion in global branded sales from drugs facing patent expiry over the 201014 period (plus $32 billion from continued erosion of already expired brands). Price cuts, reimbursement restrictions and growing regulatory pressure are further set to limit sales growth going forward.

Scope

    * Overview of the key drivers and resistors facing Pharma, Biotech and generics players out to 2014
    * Analysis of recent regulatory changes in the US, EU and emerging markets and their impact on pricing and reimbursement, drug development and marketing
    * Examination of key global and country-specific issues facing both biosimilars and generics players
    * Assessment of the impact of the global economic downturn on the Pharma and Biotech sectors and their respective counter strategies

Highlights

Annual sales growth of pharmaceuticals in the emerging markets is already double-digit, providing a key opportunity for Pharma. Revenue streams in these markets can be derived from launching branded off-patent drugs, branded generics, and local brands owned or licensed by the acquiring pharma company.

Pharma is moving away from the "me-too" and increasingly genericized primary care market towards more high value biologic therapies in secondary care as well as more niche markets; markets with little or no existing competition, and which despite their smaller size (in terms of patient numbers) are still commercially attractive.

To maintain profitability in the face of slowing sales to 2014, pharma companies have implemented a number of cost-cutting measures (in addition to strategic repositioning and diversification strategies) in order to boost profitability going forward.

Reasons to Purchase

    * Examine the combined prescription drug sales forecasts for the top 50 Pharma out to 2014 by molecule type, product source, geography and therapy area
    * Identify the key factors impacting Pharma's R&D productivity as well as the solutions companies are implementing to strengthen their R&D efforts
    * Assess key drivers behind Pharma's M&A activity and its role in boosting profits by opening up new access to new markets as well as cutting costs